There are 2789 resources available
1226P - Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: ePoster Display
1117P - Mutational landscape of large cell neuroendocrine lung carcinoma: Molecular characterization using next generation sequencing
Presenter: Maria San Roman-Gil
Session: ePoster Display
1118P - Angioside: The role of angiogenesis in lung neuroendocrine tumors according to primary tumor location in left or right parenchyma
Presenter: Anna La Salvia
Session: ePoster Display
1119P - Genomic alterations of neuroendocrine carcinoma originated from female genital tract
Presenter: MeiYu Fang
Session: ePoster Display
1120P - The prognostic and predictive roles of Ki67 and functional imaging tests in patients (pts) with metastatic pheochromocytoma or paraganglioma (mPPGL) treated with chemotherapy
Presenter: Samara Pacheco
Session: ePoster Display
1121P - Prognostic value of soluble transforming growth factor-β and soluble programmed death-ligand 1 in patients with non-functioning neuroendocrine tumors or pheochromocytomas/paragangliomas
Presenter: Jee Sun Yoon
Session: ePoster Display
1122TiP - A phase II trial to evaluate the safety and dosimetry of [<sup>177</sup>Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)
Presenter: Mark Gaze
Session: ePoster Display